Document is current
Any future updates will be listed below
-
Authors
Lin, Zhenyu
Chen, Huanpeng https://orcid.org/0000-0002-8810-0393
Ke, Yujing https://orcid.org/0009-0002-0980-6521
Xiao, Hanyue
Li, Chao https://orcid.org/0009-0009-0780-5876
Wu, Zilong
Gao, Huixin
Huang, Nanqi
Lu, Lijuan
Sun, Peng https://orcid.org/0000-0002-6589-6827
Bian, Yingjie https://orcid.org/0000-0002-9599-9907
- License Information
-
More Information
Article History
Received: 20 November 2025
Accepted: 11 May 2026
First Online: 22 May 2026
Competing interests
: A patent application related to the SLC40A1 overexpression CAR-T therapy presented in this article has been submitted by Guangzhou National Laboratory (Engineered T cell, method of constructing, and applications; Chinese patent application No. 2025118135868, under preliminary examination; PCT application No. PCT/CN2025/139780, filed). Y.B., Z.L., and H.C. are listed as inventors. The authors declare no other competing interests.
